A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.

Autor: Short NJ; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. nshort@mdanderson.org., Muftuoglu M; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Ong F; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Nasr L; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Macaron W; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Montalban-Bravo G; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Alvarado Y; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Basyal M; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Daver N; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Dinardo CD; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Borthakur G; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Jain N; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Ohanian M; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Jabbour E; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Issa GC; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bose P; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Ravandi F; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Delumpa R; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Abramova R; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Garcia-Manero G; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Andreeff M; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA., Cortes J; Georgia Cancer Center, Augusta University, Augusta, GA, USA., Kantarjian H; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

Publikováno v: Journal of hematology & oncology [J Hematol Oncol] 2023 Jul 08; Vol. 16 (1), pp. 73. Date of Electronic Publication: 2023 Jul 08.

A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.

Autor: Desikan SP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Macaron W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DeLumpa R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kwari M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: Acta haematologica [Acta Haematol] 2022; Vol. 145 (5), pp. 529-536. Date of Electronic Publication: 2022 Jun 17.

Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study.

Autor: Malakoutikhah, Zahra¹ (AUTHOR), Ashrafi, Farzaneh² (AUTHOR), Derakhshandeh, Ali² (AUTHOR)

Publikováno v: Advances in Hematology. 11/9/2023, p1-6. 6p.

Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.

Autor: Hammond, Danielle, Montalban-Bravo, Guillermo

Publikováno v: Current Hematologic Malignancy Reports; Oct2021, Vol. 16 Issue 5, p405-417, 13p

Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.

Autor: Naffouje, Rand¹ (AUTHOR) naffourd@ucmail.uc.edu, Grover, Punita¹ (AUTHOR) groverpt@ucmail.uc.edu, Yu, Hongyang^2,3 (AUTHOR) yuhong@post.kek.jp, Sendilnathan, Arun¹ (AUTHOR) arunsendil@gmail.com, Wolfe, Kara^1,4 (AUTHOR), Majd, Nazanin⁵ (AUTHOR) nkmajd@mdanderson.org, Smith, Eric P.⁶ (AUTHOR) smithep@ucmail.uc.edu, Takeuchi, Koh⁷ (AUTHOR) koh-takeuchi@aist.go.jp, Senda, Toshiya^2,3 (AUTHOR) toshiya.senda@kek.jp, Kofuji, Satoshi⁸ (AUTHOR) sakofuji@hiroshima-u.ac.jp, Sasaki, Atsuo T.^1,4,9,10 (AUTHOR) atsuo.sasaki@uc.edu

Publikováno v: Cancers. Sep2019, Vol. 11 Issue 9, p1346-1346. 1p.